I am excited to announce that we now have available the newest weight loss peptide: Retatrutide , which is currently in phase 3 trials with Lilly Pharmaceuticals and is expected to be FDA-approved by next year
Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
First a quick recap
Q14: How long should I run this stack
review at 4 mg, 9 mg, 12 mg Best For Mirrors current Phase 3 maintenance arms Approach Slow titration Duration Add 2-4 weeks per dose step when GI symptoms persist Review Point Each dose step Best For When nausea, vomiting, or diarrhea is hard to tolerate Trial protocols allowed participants to stay at the current dose for an extra 2-4 weeks when GI side effects were significant
Is Eden subject to FDA enforcement actions